A cross-linking assay allows the detection of receptors for the somatostatin analogue, lanreotide in human breast tumours

Print
Published on Thursday, 15 June 2017

Abstract

Hypothalamic somatostatin and its synthetic analogues inhibit the cell growth of several tumour models.

The somatostatin analogue lanreotide (somatuline or BIM23014C) inhibits both the in vivo and in vitro cell growth of various mammary tumours.

In order to evaluate the presence of receptors for lanreotide in breast tissue, samples from 41 female and 2 male patients were analysed by a cross-linking assay.

All the samples examined possessed at least one subtype of lanreotide binding polypeptide, however, different polypeptide patterns were observed. The two major complexes had molecular weights of 57 kD and 42 kD.

The previously demonstrated antiproliferative activity of lanreotide and the high percentage of positive tumours supports the use of lanreotide in clinical trials.

However, the role of each receptor subtype in the control of breast cell proliferation requires further characterisation.

 

 

About this publication.

 

See also:

- Somatostatin in oncology, the overlooked evidences;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonisn, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma;

- The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature;

- Pancreatic Adenocarcinoma: clinical records on 17 patients treated with Di Bella's Method;

- The Di Bella Method Increases by the 30% the survival rate for Pancreas tumors and for this reason should be proposed as first line therapy for this type of cancer;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status;

- Observations on the Report of a case of pulmonary adenocarcinoma with lymph node, hepatic and osseus metastasis.